Dolutegravir (DTG) is the only second-generation integrase inhibitor (INI) available in clinical practice. It has advantages in comparison to first generation INIs including unboosted daily dosing, limited cross resistance, and a high barrier to resistance. In clinical trials DTG proved efficacious and safe in naive and experienced patients. However, a recent study in a real life setting reported an unexpectedly high rate of discontinuation mainly due to central nervous system (CNS) events
Dolutegravir tolerability in clinical practice: results from the SCOLTA cohort
G. Pellicanò;
2016-01-01
Abstract
Dolutegravir (DTG) is the only second-generation integrase inhibitor (INI) available in clinical practice. It has advantages in comparison to first generation INIs including unboosted daily dosing, limited cross resistance, and a high barrier to resistance. In clinical trials DTG proved efficacious and safe in naive and experienced patients. However, a recent study in a real life setting reported an unexpectedly high rate of discontinuation mainly due to central nervous system (CNS) eventsFile in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Poster_230_glasgowfinal.pdf
accesso aperto
Descrizione: Poster
Tipologia:
Altro materiale allegato (es. Copertina, Indice, Materiale supplementare, Brevetti, Spin off, Start up, etc.)
Licenza:
Creative commons
Dimensione
671.93 kB
Formato
Adobe PDF
|
671.93 kB | Adobe PDF | Visualizza/Apri |
|
2016-Journal_of_the_International_AIDS_Societ_pp-168-169.pdf
accesso aperto
Descrizione: Meeting Abstract P230
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
279.74 kB
Formato
Adobe PDF
|
279.74 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
